Iobenguane I 131 (Azedra)

General information

Radioactive MIBG

Diseases for which it was used

• Pheochromocytoma

History of changes in FDA indication

• 2018-07-30: Initial approval for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. (Based on MIP-IB12B)

History of changes in PMDA indication

• 2021-09-27: Newly indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma.

Also known as

• Generic names: ¹³¹I-Metaiodobenzylguanidine, ¹³¹I-MIBG, [131I]MIBG, m-[131I]iodobenzylguanidine
• Brand name: Azedra, PheoMIBG-I 131, Raiatt MIBG-I 131